LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...

Edwards Sapien XT: company hopes to sell in China by 2013 Edwards Lifesciences Corp. of Irvine now has a date with regulators for its highly touted Edwards Sapien heart valve. The medical device maker ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

A U.S. court blocked Edwards Lifesciences' planned JenaValve acquisition after an FTC challenge. The company disagrees with ...

Edwards Lifesciences Corp.’s fast-growing Sapien replacement heart valve could hit the U.S. in October, the company said last week as part of its first-quarter earnings report. Sapien doesn’t require ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and ...

Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...